PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS

Abstract INTRODUCTION Previously thought to be rare, recent case series have shown that IDH mutations in young patients are more common than previously described. In this study, we analyzed IDH-mutant tumors to determine clinical significance of these mutations in children, adolescents and young adu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2020-12, Vol.22 (Supplement_3), p.iii427-iii427
Hauptverfasser: Bornhorst, Miriam, Nobre, Liana, Zapotocky, Michal, Barseghyan, Hayk, Goecks, Jeremy, Boue, Daniel, Tabori, Uri, Hawkins, Cynthia, Bouffet, Eric, MacDonald, Tobey, Schniederjan, Matthew, Bronischer, Alberto, Orr, Brent, Solomon, David, Mueller, Sabine, Opocher, Enrico, Vortmeyer, Alexander, Marks, Asher, Koschmann, Carl, Leung, Denise Leung, Mody, Rajen, Hwang, Eugene, Bhattacharya, Surajit, Vilain, Eric, Turner, Joyce, Kilburn, Lindsay, Rood, Brian, Packer, Roger, Nazarian, Javad, Ho, Cheng-Ying
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract INTRODUCTION Previously thought to be rare, recent case series have shown that IDH mutations in young patients are more common than previously described. In this study, we analyzed IDH-mutant tumors to determine clinical significance of these mutations in children, adolescents and young adults. METHODS Through this multi-institution study (10 institutions), we collected 64 IDH1/2-mutant infiltrating astrocytoma specimens from 58 patients aged 4–26 (M:F, 0.4:0.6). Specimens included 46 low-grade (LGG) and 18 high-grade (HGG) astrocytomas. Tumor sequencing data (n=45), germline sequencing data (n=37) and outcome data (n=40) was analyzed. RESULTS Similar to adults, most sequenced tumors had a co-mutation in the TP53 gene, while ATRX mutations were less common and primarily seen in HGGs. Approximately 60% (n=21) of patients with germline data available had a mutation in a cancer predisposition gene. Mismatch repair (MMR) mutations were most common (n=12; MSH6 n=9), followed by TP53mutations (n=7). All patients with MMR gene mutations had HGGs and poor progression free (PFS=10% at 2 years, mean TTP=9 months) and overall (OS
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noaa222.649